10.87
+0.04(+0.37%)
Currency In USD
| Previous Close | 10.83 |
| Open | 11.18 |
| Day High | 11.18 |
| Day Low | 10.33 |
| 52-Week High | 27.5 |
| 52-Week Low | 4.81 |
| Volume | 392,315 |
| Average Volume | 416,316 |
| Market Cap | 365.17M |
| PE | -1.74 |
| EPS | -6.23 |
| Moving Average 50 Days | 13 |
| Moving Average 200 Days | 12.29 |
| Change | 0.04 |
If you invested $1000 in MBX Biosciences, Inc. Common Stock (MBX) since IPO date, it would be worth $459.62 as of September 16, 2025 at a share price of $10.87. Whereas If you bought $1000 worth of MBX Biosciences, Inc. Common Stock (MBX) shares 1 year ago, it would be worth $459.62 as of September 16, 2025 at a share price of $10.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
GlobeNewswire Inc.
Sep 04, 2025 12:00 PM GMT
Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291CARMEL, Ind., Sept. 04, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical co
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
GlobeNewswire Inc.
Jun 23, 2025 12:00 PM GMT
Dr. Moraitis brings deep experience in endocrinology to his role leading clinical development for MBX’s lead product candidate, canvuparatideCARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage bioph
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
GlobeNewswire Inc.
Jun 16, 2025 12:00 PM GMT
GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX’s novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 2025 CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE)